NO20012690L - Fremgangsmåte for å redusere serumglukose og triglyceridnivåer og for å inhibere angiogenese ved bruk avindolalkansyrer - Google Patents

Fremgangsmåte for å redusere serumglukose og triglyceridnivåer og for å inhibere angiogenese ved bruk avindolalkansyrer

Info

Publication number
NO20012690L
NO20012690L NO20012690A NO20012690A NO20012690L NO 20012690 L NO20012690 L NO 20012690L NO 20012690 A NO20012690 A NO 20012690A NO 20012690 A NO20012690 A NO 20012690A NO 20012690 L NO20012690 L NO 20012690L
Authority
NO
Norway
Prior art keywords
triglyceride levels
alkanoic acids
inhibiting angiogenesis
serum glucose
reducing serum
Prior art date
Application number
NO20012690A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012690D0 (no
Inventor
Janet Sredy
Jorge Jacot
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of NO20012690D0 publication Critical patent/NO20012690D0/no
Publication of NO20012690L publication Critical patent/NO20012690L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20012690A 1998-12-01 2001-05-31 Fremgangsmåte for å redusere serumglukose og triglyceridnivåer og for å inhibere angiogenese ved bruk avindolalkansyrer NO20012690L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11039598P 1998-12-01 1998-12-01
PCT/US1999/028483 WO2000032180A2 (en) 1998-12-01 1999-12-01 Antihypertriglyceridemic, antihyperglycemic, anti-angiogenic and wound healing substituted indolealkanoic acids

Publications (2)

Publication Number Publication Date
NO20012690D0 NO20012690D0 (no) 2001-05-31
NO20012690L true NO20012690L (no) 2001-07-27

Family

ID=22332786

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012690A NO20012690L (no) 1998-12-01 2001-05-31 Fremgangsmåte for å redusere serumglukose og triglyceridnivåer og for å inhibere angiogenese ved bruk avindolalkansyrer

Country Status (30)

Country Link
US (5) US6555568B1 (id)
EP (1) EP1135124B1 (id)
JP (1) JP2002531398A (id)
KR (1) KR20010086075A (id)
CN (1) CN1368883A (id)
AP (1) AP2001002146A0 (id)
AT (1) ATE265210T1 (id)
AU (1) AU770925B2 (id)
BG (1) BG105531A (id)
BR (1) BR9915882A (id)
CA (1) CA2385845A1 (id)
CZ (1) CZ20011864A3 (id)
DE (1) DE69916881T2 (id)
DZ (1) DZ2953A1 (id)
EE (1) EE200100296A (id)
HK (1) HK1046372A1 (id)
HU (1) HUP0104953A3 (id)
ID (1) ID30037A (id)
IL (1) IL143247A0 (id)
MX (1) MXPA02003118A (id)
NO (1) NO20012690L (id)
OA (1) OA12035A (id)
PL (1) PL349016A1 (id)
SK (1) SK7352001A3 (id)
TN (1) TNSN99224A1 (id)
TR (1) TR200101539T2 (id)
TW (1) TW584560B (id)
WO (1) WO2000032180A2 (id)
YU (1) YU40101A (id)
ZA (1) ZA200104126B (id)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1066283B1 (en) * 1998-03-31 2004-06-23 The Institutes for Pharmaceutical Discovery, Inc. Substituted indolealkanoic acids
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
AU2001238718A1 (en) * 2000-03-02 2001-09-12 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
AU2001259668A1 (en) * 2000-05-09 2001-11-20 The Institute For Pharmaceutical Discovery Llc Methods for testing compounds useful for treating diabetic complications
DK1397130T3 (da) 2001-06-20 2007-11-12 Wyeth Corp Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE60306548T2 (de) 2002-12-10 2007-06-21 Wyeth Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2003296323A1 (en) 2002-12-10 2004-06-30 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CN1723197A (zh) 2002-12-10 2006-01-18 惠氏公司 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－烷基和3－芳基烷基1h－吲哚－1－基乙酸衍生物
JP4828414B2 (ja) * 2003-04-28 2011-11-30 ニツポネツクス・インコーポレーテツド インドール酢酸誘導体および薬剤としてのそれらの使用
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
MX2007002178A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de oxazolo-naftilo como moduladores del inhibidor del activador de plasminogeno tipo 1 (pai-1) util en el tratamiento de trombosis y enfermedades cardiovasculares.
EP1833787A2 (en) * 2004-11-30 2007-09-19 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
CA2588953A1 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Ppar active compounds
AU2006279496A1 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
CA2621474A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1,3-disubstituted indole derivatives for use as ppar modulators
DK2046740T3 (da) 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
PT2250161E (pt) 2008-01-18 2014-01-21 Atopix Therapeutics Ltd Compostos tendo atividade antagonista de crth2
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
US20100022613A1 (en) 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4442118A (en) * 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
EP0222576B1 (en) 1985-11-07 1992-03-18 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4960785A (en) 1988-12-16 1990-10-02 Pfizer Inc. Indolinone derivatives
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4868301A (en) 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US5064852A (en) * 1988-12-16 1991-11-12 Pfizer Inc. Indolinone derivatives
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
US5304557A (en) 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
US5312829A (en) * 1990-05-21 1994-05-17 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5236945A (en) 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5116753A (en) * 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
JP3195455B2 (ja) 1993-01-06 2001-08-06 ウェルファイド株式会社 キノリン−３−酢酸誘導体、その製造法と用途
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
AU7634694A (en) 1993-08-20 1995-03-21 University Of Medicine And Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
TW401301B (en) * 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5700819A (en) 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
JPH09165371A (ja) 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
EP1066283B1 (en) * 1998-03-31 2004-06-23 The Institutes for Pharmaceutical Discovery, Inc. Substituted indolealkanoic acids
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
AU2001238718A1 (en) * 2000-03-02 2001-09-12 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Also Published As

Publication number Publication date
TW584560B (en) 2004-04-21
OA12035A (en) 2006-05-02
EP1135124B1 (en) 2004-04-28
CN1368883A (zh) 2002-09-11
JP2002531398A (ja) 2002-09-24
US6964980B2 (en) 2005-11-15
EE200100296A (et) 2003-02-17
MXPA02003118A (es) 2004-04-21
AU770925B2 (en) 2004-03-11
HUP0104953A2 (hu) 2002-07-29
US6555568B1 (en) 2003-04-29
US20030216452A1 (en) 2003-11-20
ATE265210T1 (de) 2004-05-15
DE69916881T2 (de) 2005-02-03
AU2161600A (en) 2000-06-19
BG105531A (en) 2001-12-31
YU40101A (sh) 2005-07-19
HK1046372A1 (zh) 2003-01-10
BR9915882A (pt) 2001-08-21
CA2385845A1 (en) 2000-06-08
US20100324105A1 (en) 2010-12-23
PL349016A1 (en) 2002-06-17
US20120065203A1 (en) 2012-03-15
WO2000032180A2 (en) 2000-06-08
TR200101539T2 (tr) 2001-12-21
KR20010086075A (ko) 2001-09-07
WO2000032180A3 (en) 2000-11-16
CZ20011864A3 (cs) 2002-03-13
EP1135124A2 (en) 2001-09-26
TNSN99224A1 (fr) 2005-11-10
DZ2953A1 (fr) 2004-03-15
HUP0104953A3 (en) 2002-08-28
DE69916881D1 (de) 2004-06-03
NO20012690D0 (no) 2001-05-31
AP2001002146A0 (en) 2001-06-30
SK7352001A3 (en) 2002-06-04
US20060074114A1 (en) 2006-04-06
ZA200104126B (en) 2002-05-21
ID30037A (id) 2001-11-01
IL143247A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
NO20012690D0 (no) Fremgangsmåte for å redusere serumglukose og triglyceridnivåer og for å inhibere angiogenese ved bruk avindolalkansyrer
PT1316620E (pt) Processo de pr?-hidr?lise de biomassa
NO20004900L (no) Substituerte indolalkansyrer
GB9820913D0 (en) Method & apparatus for top to bottom expansion of tubulars
EE200000241A (et) 8-metoksükinoloonkarboksüülhapete valmistamismeetod
EP1200538A4 (en) METHOD FOR TREATING PETROLEUMIC ACIDS
NO20001777D0 (no) Fremgangsmåte for fremstilling av substituerte 4-fenyl-4- cyanocykloheksankarboksylsyrer
ID21199A (id) Proses untuk mencegah pembentukan kerak dalam proses pembuatan-kertas
AU3436299A (en) Process for the production of acetic acid and/or acetic anhydride
NO991146L (no) FremgangsmÕte ved overflatebehandling
NO985757D0 (no) FremgangsmÕte ved fremstilling av rustfritt stÕl
PL336836A1 (en) Method of obtaining aminoaryl sulphonic acids
AU3959499A (en) Process of purifying angiogenesis inhibitors
ID28417A (id) Metode memperbaiki permukaan produk logam
NO20006383D0 (no) Fremgangsmåte for behandling
GB2333773B (en) Process for the production of acetic anhydride
NO994108D0 (no) Fremgangsmåte ved fremstilling av 4H-4-okso-kinolizin-3-karboksylsyrederivater
NO995678D0 (no) Fremgangsmåte for fremstilling av 5-okso-3-fenyl-3-cykloheksenkarboksylsyre
NO20005396D0 (no) FremgangsmÕte for bioteknologisk oksydasjon av substituerte trimetylsykloheksenylforbindelser
DE69908442D1 (de) Verfahren zum Herstellen von Maleinsäureanhydrid
NO20014449L (no) Fremgangsmåte for fremstilling av 5-amino-8- alkylkinolonkarboksylsyrederivater og mellomprodukter ifremstillingen derav
ID28976A (id) Proses untuk penyiapan ester beta-gama tak jenuh
AU5980699A (en) Process for the manufacture of quaternary carboxylic acids
NO980194L (no) Fremgangsmåte for vasking ved å anvende polykarboksylsyresalter
HK1054249A1 (en) Process for pre-hydrolysis of biomass

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application